JUST-AAV
Live / Applied — Non-final action mailed (as of 27 Feb 2026)
What this means for you
Not registered yet, but its 25 Jul 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79440017
- Mark type
- Stylized text
- Filed
- 25 Jul 2025
Goods and services
- Class 001 — Chemicals: Chemicals for use in industry and science; diagnostic reagents for scientific or research use; biological preparations for use in industry and science; chemical reagents, other than for medical or veterinary purpose; biochemical reagents used for non-medical purposes; diagnostic reagents and preparations, except for medical or veterinary use; chemical reagents for use in genetic research, other than for medical or veterinary use; chemicals and biochemical products for use in gene delivery technology, other than for medical or veterinary use; active chemical ingredients for use in the manufacture of pharmaceuticals; biological materials, namely, adeno-associated viruses (AAVs), AAV particles and AAV plasmids, all for scientific and research purposes and not for medical and veterinary purposes; biological materials, namely, viral vectors in the nature of genetically modified viruses for scientific and research purposes; adeno-associated virus (AAV) vectors, protein sequences and nucleic acid sequences for use in scientific research and pharmaceutical research; nucleic acid sequences, other than for medical or veterinary purposes
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for gene therapy for the treatment of genetic diseases or disorders; pharmaceutical preparations for use in the treatment of gene therapy treatable diseases; pharmaceutical preparations containing adeno-associated virus (AAV) protein sequences and nucleic acid sequences for use in gene delivery; therapeutic drugs and agents for use in treatment of growth hormone deficiency, lysosomal disease and renal anemia; therapeutic drugs and agents for applications in regenerative medicine; chemotherapeutics; organotherapy preparations; biological preparations for gene therapy for the treatment of genetic diseases or disorders; biological preparations for use in the treatment of gene therapy treatable diseases; gene therapy products, namely, biopharmaceutical preparations primarily composed of adeno-associated virus (AAV) vectors comprising of a transgene or other nucleic acid payload for delivery to a cell or tissue; biological preparations for gene therapy; reagents for medical or veterinary purposes; antibodies for medical or veterinary purposes; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; viral vectors for medical use relating to gene therapy; gene therapy preparations for neurological diseases; pharmaceutical preparations acting on the central nervous system; nucleic acid sequences for medical and veterinary purposes; cells for medical or clinical use; enzymes for medical purposes
- Class 042 — Scientific and technological services: Medical research; chemical research; testing, inspection or research in the field of chemistry; chemical analysis; medical and scientific research, namely, conducting clinical trials for others; testing, inspection or research of pharmaceuticals; gene therapy research; development of gene-based medicines; research and development services relating to medicines; research and development in the field of biotechnology; development of new technology for others in the field of medicine, science, and chemistry; research and development of new products for others; laboratory services for biomanufacturing; scientific research; providing medical and scientific research information in the field of pharmaceuticals; research and development services in the field of platform technologies for genetic delivery of therapies and pharmaceuticals; consultation and research in the field of gene delivery technology; consultation and research in the field of drug delivery technology; research and development of vaccines; quality control for others
Owner
Prosecution history
- 19 Mar 2026 — REFUSAL PROCESSED BY IB
- 27 Feb 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 27 Feb 2026 — REFUSAL PROCESSED BY MPU
- 31 Jan 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 30 Jan 2026 — NON-FINAL ACTION WRITTEN
- 21 Jan 2026 — ASSIGNED TO EXAMINER
- 20 Jan 2026 — APPLICATION FILING RECEIPT MAILED
- 20 Jan 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 18 Jan 2026 — LIMITATION FROM ORIGINAL APPLICATION ENTERED
- 25 Dec 2025 — SN ASSIGNED FOR SECT 66A APPL FROM IB